Literature DB >> 22123290

American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited.

Armando A Juliao1, Mauricio Plata, Amir Kazzazi, Yakup Bostanci, Bob Djavan.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to provide a complete revision of two of the most widely used clinical guidelines in the management of lower urinary tract symptoms induced by benign prostatic hyperplasia and their importance and compliance among urologists. RECENT
FINDINGS: Updates of the American Association of Urology and European Association of Urology clinical practice guidelines (CPGs) were reviewed and analyzed. Literature concerning compliance and application of these two CPGs in the different working scenarios of practicing has been evaluated.
SUMMARY: Urology has moved to an era in which costs and quality of care are being scrutinized, and compliance to CPGs will be assessed. Practicing urologists do not have the time to keep up to date with the continuous incoming literature and CPGs are a great tool to give the highest quality of care to our patients.

Entities:  

Mesh:

Year:  2012        PMID: 22123290     DOI: 10.1097/MOU.0b013e32834d8e87

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  8 in total

1.  Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

Authors:  Li Tao Zhang; Jong Kwan Park
Journal:  World J Nephrol       Date:  2015-02-06

2.  Laser prostatectomy: holmium laser enucleation and photoselective laser vaporization of the prostate.

Authors:  Yakup Bostanci; Amir Kazzazi; Bob Djavan
Journal:  Rev Urol       Date:  2013

3.  Comprehensive urinary metabolomic characterization of a genetically induced mouse model of prostatic inflammation.

Authors:  Ling Hao; Yatao Shi; Samuel Thomas; Chad M Vezina; Sagar Bajpai; Arya Ashok; Charles J Bieberich; William A Ricke; Lingjun Li
Journal:  Int J Mass Spectrom       Date:  2018-09-22       Impact factor: 1.986

Review 4.  Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Jiye Kim; Roderick MacDonald; Balaji Reddy; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

5.  LPS/TLR4 Signaling Enhances TGF-β Response Through Downregulating BAMBI During Prostatic Hyperplasia.

Authors:  Yao He; Zhenyu Ou; Xiang Chen; Xiongbing Zu; Longfei Liu; Yuan Li; Zhenzhen Cao; Minfeng Chen; Zhi Chen; Hequn Chen; Lin Qi; Long Wang
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

Review 6.  Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.

Authors:  Zhao-Jun Yu; Hai-Lan Yan; Fang-Hua Xu; Hai-Chao Chao; Lei-Hong Deng; Xiang-Da Xu; Jian-Biao Huang; Tao Zeng
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

7.  In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms.

Authors:  Ling Hao; Tyler Greer; David Page; Yatao Shi; Chad M Vezina; Jill A Macoska; Paul C Marker; Dale E Bjorling; Wade Bushman; William A Ricke; Lingjun Li
Journal:  Sci Rep       Date:  2016-08-09       Impact factor: 4.379

8.  Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.

Authors:  Salvatore D'Agate; Chandrashekhar Chavan; Michael Manyak; Juan Manuel Palacios-Moreno; Matthias Oelke; Martin C Michel; Claus G Roehrborn; Oscar Della Pasqua
Journal:  World J Urol       Date:  2020-12-18       Impact factor: 4.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.